MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 326639 | Name: Aviptadil Acetate
Featured New

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Aviptadil is a vasoactive intestinal polypeptide (VIP). Aviptadil in combination with phentolamine and sexual stimulation, is expected to provide a new and effective alternative for erectile dysfunction (ED) patients that is essentially free of the troublesome side effects and cumbersome delivery methods which limit the use of other pharmacologic preparations.

Chemical Structure

Aviptadil Acetate
Aviptadil Acetate
CAS#40077-57-4 (free base)

Theoretical Analysis

MedKoo Cat#: 326639

Name: Aviptadil Acetate

CAS#: 40077-57-4 (free base)

Chemical Formula: C155H253N43O51S

Exact Mass: 0.0000

Molecular Weight: 3567.04

Elemental Analysis: C, 52.19; H, 7.15; N, 16.89; O, 22.87; S, 0.90

Price and Availability

Size Price Availability Quantity
1mg USD 385.00 2 Weeks
1g USD 4,850.00 2 Weeks
2g USD 7,950.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Aviptadil Acetate; VIP; Invicorp.
IUPAC/Chemical Name
H-His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH2 tetraacetic acid.
InChi Key
CBTPBFFYMHBLFP-KQVGQEDNSA-N
InChi Code
InChI=1S/C147H237N43O43S.4C2H4O2/c1-18-75(12)115(142(229)180-96(56-72(6)7)131(218)183-104(145(232)233)63-110(155)200)188-139(226)106(68-192)185-134(221)101(62-109(154)199)177-130(217)95(55-71(4)5)174-132(219)97(58-81-37-41-84(195)42-38-81)175-125(212)88(33-23-26-49-149)167-123(210)89(34-24-27-50-150)171-140(227)113(73(8)9)186-118(205)76(13)164-121(208)93(47-53-234-17)170-127(214)92(45-46-107(152)197)169-122(209)87(32-22-25-48-148)166-124(211)90(35-28-51-161-146(156)157)168-129(216)94(54-70(2)3)173-126(213)91(36-29-52-162-147(158)159)172-143(230)116(78(15)193)189-136(223)98(59-82-39-43-85(196)44-40-82)176-133(220)100(61-108(153)198)178-135(222)103(65-112(203)204)182-144(231)117(79(16)194)190-137(224)99(57-80-30-20-19-21-31-80)181-141(228)114(74(10)11)187-119(206)77(14)165-128(215)102(64-111(201)202)179-138(225)105(67-191)184-120(207)86(151)60-83-66-160-69-163-83;4*1-2(3)4/h19-21,30-31,37-44,66,69-79,86-106,113-117,191-196H,18,22-29,32-36,45-65,67-68,148-151H2,1-17H3,(H2,152,197)(H2,153,198)(H2,154,199)(H2,155,200)(H,160,163)(H,164,208)(H,165,215)(H,166,211)(H,167,210)(H,168,216)(H,169,209)(H,170,214)(H,171,227)(H,172,230)(H,173,213)(H,174,219)(H,175,212)(H,176,220)(H,177,217)(H,178,222)(H,179,225)(H,180,229)(H,181,228)(H,182,231)(H,183,218)(H,184,207)(H,185,221)(H,186,205)(H,187,206)(H,188,226)(H,189,223)(H,190,224)(H,201,202)(H,203,204)(H,232,233)(H4,156,157,161)(H4,158,159,162);4*1H3,(H,3,4)/t75-,76-,77-,78+,79+,86-,87-,88-,89-,90-,91-,92-,93-,94-,95-,96-,97-,98-,99-,100-,101-,102-,103-,104-,105-,106-,113-,114-,115-,116-,117-;;;;/m0..../s1
SMILES Code
O=C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](C)C(N[C@@H](C(C)C)C(N[C@@H](CC1=CC=CC=C1)C(N[C@@H]([C@H](O)C)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(N)=O)C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC(C)C)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CCCCN)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCSC)C(N[C@@H](C)C(N[C@@H](C(C)C)C(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CC3=CC=C(C=C3)O)C(N[C@@H](CC(C)C)C(N[C@@H](CC(N)=O)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC(C)C)C(N[C@@H](CC(N)=O)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC4=CNC=N4)N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O
Appearance
Solid powder
Purity
>95% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 3,567.04 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Keijzers GB. Aviptadil (Senatek). Curr Opin Investig Drugs. 2001 Apr;2(4):545-9. PMID: 11566015. 2: Mukherjee T, Behl T, Sharma S, Sehgal A, Singh S, Sharma N, Mathew B, Kaur J, Kaur R, Das M, Aleya L, Bungau S. Anticipated pharmacological role of Aviptadil on COVID-19. Environ Sci Pollut Res Int. 2022 Feb;29(6):8109-8125. doi: 10.1007/s11356-021-17824-5. Epub 2021 Nov 30. PMID: 34846667; PMCID: PMC8630992. 3: Boesing M, Abig K, Brändle M, Brutsche M, Burri E, Frye BC, Giezendanner S, Grutters JC, Haas P, Heisler J, Jaun F, Leuppi-Taegtmeyer AB, Lüthi-Corridori G, Müller-Quernheim J, Nüesch R, Pohl W, Rassouli F, Leuppi JD. Inhaled aviptadil for the possible treatment of COVID-19 in patients at high risk for ARDS: study protocol for a randomized, placebo-controlled, and multicenter trial. Trials. 2022 Sep 20;23(1):790. doi: 10.1186/s13063-022-06723-w. PMID: 36127739; PMCID: PMC9486780. 4: Auld SC. Aviptadil for COVID-19: A Case Study and Call to Action About the Challenges of Research During a Global Pandemic. Crit Care Med. 2022 Nov 1;50(11):1662-1664. doi: 10.1097/CCM.0000000000005686. Epub 2022 Oct 13. PMID: 36227034; PMCID: PMC9555556. 5: Youssef JG, Lavin P, Schoenfeld DA, Lee RA, Lenhardt R, Park DJ, Fernandez JP, Morganroth ML, Javitt JC, Jayaweera D. The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial. Crit Care Med. 2022 Nov 1;50(11):1545-1554. doi: 10.1097/CCM.0000000000005660. Epub 2022 Aug 29. PMID: 36044317; PMCID: PMC9555831. 6: Gross PC, Burkart SC, Müller R. Analytics of the therapeutic peptide aviptadil by sheathless CE-MS and comparison with nanoRP-HPLC-MS. J Pharm Biomed Anal. 2014 Jan;88:477-82. doi: 10.1016/j.jpba.2013.09.024. Epub 2013 Oct 5. PMID: 24176753. 7: Couvineau A, Gomariz RP, Tan YV. Editorial: GPCR in Inflammatory and Cancer Diseases. Front Endocrinol (Lausanne). 2020 Sep 25;11:588157. doi: 10.3389/fendo.2020.588157. PMID: 33101216; PMCID: PMC7545348. 8: Leuchte HH, Baezner C, Baumgartner RA, Bevec D, Bacher G, Neurohr C, Behr J. Inhalation of vasoactive intestinal peptide in pulmonary hypertension. Eur Respir J. 2008 Nov;32(5):1289-94. doi: 10.1183/09031936.00050008. PMID: 18978135. 9: Bode SFN, Rohr J, Müller Quernheim J, Seidl M, Speckmann C, Heinzmann A. Pulmonary granulomatosis of genetic origin. Eur Respir Rev. 2021 Apr 29;30(160):200152. doi: 10.1183/16000617.0152-2020. PMID: 33927005; PMCID: PMC9488645. 10: Hu J, Xu Q, McTiernan C, Lai YC, Osei-Hwedieh D, Gladwin M. Novel Targets of Drug Treatment for Pulmonary Hypertension. Am J Cardiovasc Drugs. 2015 Aug;15(4):225-34. doi: 10.1007/s40256-015-0125-4. PMID: 26016608. 11: Youssef JG, Bitar MZ, Zahiruddin F, Al-Saadi M, Elshawwaf M, Yau S, Goodarzi A, Javitt JC. Brief Report: Rapid Clinical Recovery From Critical Coronavirus Disease 2019 With Respiratory Failure in a Pregnant Patient Treated With IV Vasoactive Intestinal Peptide. Crit Care Explor. 2022 Jan 5;4(1):e0607. doi: 10.1097/CCE.0000000000000607. PMID: 35018346; PMCID: PMC8735760. 12: Khurdayan VK, Bozzo J, Prous JR. Chronicles in drug discovery. Drug News Perspect. 2005 Oct;18(8):517-22. doi: 10.1358/dnp.2005.18.8.953409. PMID: 16391721. 13: Mucke HA. Pulmonary arterial hypertension: on the way to a manageable disease. Curr Opin Investig Drugs. 2008 Sep;9(9):957-62. PMID: 18729002. 14: Duncan C, Omran GJ, Teh J, Davis NF, Bolton DM, Lawrentschuk N. Erectile dysfunction: a global review of intracavernosal injectables. World J Urol. 2019 Jun;37(6):1007-1014. doi: 10.1007/s00345-019-02727-5. Epub 2019 Mar 20. PMID: 30895359. 15: Lythgoe MP, Rhodes CJ, Ghataorhe P, Attard M, Wharton J, Wilkins MR. Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future. Pharmacol Ther. 2016 Aug;164:195-203. doi: 10.1016/j.pharmthera.2016.04.012. Epub 2016 Apr 29. PMID: 27133570. 16: Frye BC, Meiss F, von Bubnoff D, Zissel G, Müller-Quernheim J. Vasoactive Intestinal Peptide in Checkpoint Inhibitor-Induced Pneumonitis. N Engl J Med. 2020 Jun 25;382(26):2573-2574. doi: 10.1056/NEJMc2000343. PMID: 32579820. 17: Dinsmore WW, Wyllie MG. Vasoactive intestinal polypeptide/phentolamine for intracavernosal injection in erectile dysfunction. BJU Int. 2008 Sep;102(8):933-7. doi: 10.1111/j.1464-410X.2008.07764.x. Epub 2008 May 15. PMID: 18485029. 18: Porst H. Reflexionen über 50 Jahre Sexualmedizin in der Urologie mit Fokus auf männliche Sexualstörungen [Reflexions on 50 Years of Sexual Medicine in Urology Focusing on Male Sexual Dysfunctions]. Aktuelle Urol. 2019 Jul;50(3):248-267. German. doi: 10.1055/a-0953-5034. Epub 2019 Jul 23. PMID: 31342492. 19: Alnomasy SF, Alotaibi BS, Aldosari ZM, Mujamammi AH, Alzamami A, Anand P, Akhter Y, Khan FR, Hasan MR. Molecular Interactions of Zyesami with the SARS- CoV-2 nsp10/nsp16 Protein Complex. Comb Chem High Throughput Screen. 2023;26(6):1196-1203. doi: 10.2174/1386207325666220816141028. PMID: 35975856. 20: Wyllie MG. The anatomy of drug development: Invicorp, a product before its time. BJU Int. 2010 Sep;106(5):723-4. doi: 10.1111/j.1464-410X.2010.09603.x. PMID: 21050351.